Want to contact a Zometa attorney in Washington, DC?...Get a free case evaluation from one of our Zometa attorneys in Washington, DC now.
Home : Unsafe Drugs : Zometa : MSN Newsfeeds
Zometa - MSN Newsfeeds
- News Busters - ... could save lives of people fighting osteoporosis, but neither ABC “World News with Charles Gibson,” nor CBS “Evening News” even mentioned the drug’s manufacturer - Novartis Pharmaceuticals (NYSE: NVS ) - in May 2 broadcasts. Zoledronic acid ...
- News Busters - ... could save lives of people fighting osteoporosis, but neither ABC “World News with Charles Gibson,” nor CBS “Evening News” even mentioned the drug’s manufacturer - Novartis Pharmaceuticals (NYSE: NVS ) - in May 2 broadcasts. Zoledronic acid ...
- News Busters - ... could save lives of people fighting osteoporosis, but neither ABC “World News with Charles Gibson,” nor CBS “Evening News” even mentioned the drug’s manufacturer - Novartis Pharmaceuticals (NYSE: NVS ) - in May 2 broadcasts. Zoledronic acid ...
- News Busters - ... could save lives of people fighting osteoporosis, but neither ABC “World News with Charles Gibson,” nor CBS “Evening News” even mentioned the drug’s manufacturer - Novartis Pharmaceuticals (NYSE: NVS ) - in May 2 broadcasts. Zoledronic acid ...
- United Press International - SAN DIEGO, May 9 (UPI) -- A once-a-year treatment with zoledronic acid -- sold as Zometa -- can help women with osteoporosis avoid hip and back fractures, say U.S. doctors. "Compared to placebo, once-yearly infusion with Zometa for three years ...
- Heart Info - (Ivanhoe Newswire) -- Postmenopausal women with osteoporosis may only need one dose of medication per year to reduce the risk of fractures. A new study looked at the effects of annual doses of zoledronic acid (Reclast) in postmenopausal women between ...
- Jackson Clarion-Ledger - The study of 7,736 postmenopausal women with osteoporosis focuses on Reclast, known generically as zoledronic acid. In the new study, funded by Novartis, the risk of a serious case of irregular heart rhythm was more than double that in the other ...
- Wall Street Journal - It could also prove a boon for Novartis Pharmaceuticals Corp., the East Hanover, N.J., maker of the drug, zoledronic acid, which it plans to sell under the name Reclast. The international study found that the risk of spine fractures in patients ...
- US News and World Report - Women who received once-yearly infusions of zoledronic acid (Reclast) had a 70 percent lower risk of vertebral fracture over three years than those on a placebo; previous studies put the Fosamax number at 40 percent. One caveat: The drug also ...
- US News and World Report - The large, multicenter trial compared 3,889 women who received once-yearly infusions of zoledronic acid (Reclast), a drug chemically similar to Fosamax, with 3,876 who got a placebo over three years and found that the zoledronic acid reduced the risk ...
- Associated Press - Novartis recently won approval to sell Reclast, known generically as zoledronic acid, for Paget's disease, another bone condition. The company hopes to get an OK later this year to sell it for osteoporosis use. The new study, funded by Novartis, shows ...
- Baltimore Sun - She went for her first dose of intravenous Zometa on Tuesday and said the entire doctor's visit took about an hour. Doctors hope patients such as Hemmes will be better at sticking with the intravenous treatments. Even though the FDA hasn't ...
- MSN UK News - A annual osteoporosis treatment has been found to significantly reduce the risk of life-threatening bone fractures. During trials in the US, almost 8,000 women were given annual 15-minute infusions of zoledronic acid or a placebo over a three-year ...
- Boston Online - The drug already is sold by drug maker Novartis in the United States under the brand name Zometa for the treatment of Paget's disease -- a genetic disorder in which bone becomes soft and breaks down readily -- and the prevention of bone loss in ...
- News Busters - While both programs showed plenty of love to the new wonder drug, there was no love for Novartis and no mention of the millions of dollars they spent developing the product which is marketed as Reclast and Zometa. The Pharmaceutical Research and ...
- RxPG - The study showed bone mineral density increased significantly in the spine by 6.7 percent and in the hip by 6 percent in women on Reclast compared to those who received placebo. Zoledronic acid belongs to a class of drugs called bisphosphonates ...
- Newsday - Reclast - whose scientific name is zoledronic acid - reduced spinal fractures by 70 percent and hip fractures by 41 percent during the three-year study period. Osteoporosis is a major public health issue, affecting 10 million people nationwide, 8 ...
- Philadelphia Daily News - Novartis Pharmaceuticals Corp. got approval six years ago to market zoledronic acid as Zometa for cancer-related bone weakening. The North Jersey-based company hopes that, with the latest results, it will get the Food and Drug Administration's ...
- Baltimore Sun - She went for her first dose of intravenous Zometa on Tuesday and said the entire doctor's visit took about an hour. Doctors hope patients such as Hemmes will be better at sticking with the intravenous treatments. Even though the FDA hasn't ...
- WHEC TV-10 - There's a promising new drug for osteoporosis, offeringhope for patients who have trouble remembering to take a weekly or monthly pill. The study on Zometa appears in the New England Journal of Medicine, comparing women receiving the yearly infusion ...
Want to contact a Zometa attorney in Washington, DC?...Get a free case evaluation from one of our Zometa attorneys in Washington, DC now.
Pages: Previous 1 2 3 4 5 6 Next
These articles are related to: Zometa Lawsuit, Zometa Law Suit, Zometa Law Firm, Zometa Lawyer, Zometa Attorney, Zometa Trial, Zometa Verdict, Zometa News, Zometa Information, Zometa Lawyers, Zometa Warning, Zometa Class Action, Zometa Litigation, Zometa Side Effects, Zometa Recall, Zometa Warning, Zometa Abuse
